> top > docs > PMC:1283364 > spans > 48164-49687 > annotations

PMC:1283364 / 48164-49687 JSONTXT

Annnotations TAB JSON ListView MergeView

craft-sa-dev

Id Subject Object Predicate Lexical cue
T10541 0-2 PRP denotes We
T10542 3-10 VBP denotes present
T10543 11-12 DT denotes a
T10544 23-28 NN denotes model
T10545 13-16 JJ denotes new
T10546 17-22 NN denotes mouse
T10547 29-32 IN denotes for
T10548 33-35 NN denotes AD
T10549 36-40 WDT denotes that
T10550 45-53 VBN denotes designed
T10551 41-44 VBD denotes was
T10552 54-56 TO denotes to
T10553 57-61 VB denotes test
T10554 62-65 DT denotes the
T10555 66-78 NNS denotes consequences
T10556 79-81 IN denotes of
T10557 82-92 VBG denotes inhibiting
T10558 93-95 NN denotes Aβ
T10559 96-106 NN denotes production
T10560 107-112 IN denotes after
T10561 113-116 DT denotes the
T10562 117-122 NN denotes onset
T10563 123-125 IN denotes of
T10564 126-133 NN denotes amyloid
T10565 134-143 NN denotes pathology
T10566 143-144 . denotes .
T10567 144-299 sentence denotes New lines of transgenic mice were developed for this study that express high levels of APPswe/ind under the control of a tetracycline-responsive promoter.
T10568 145-148 JJ denotes New
T10569 149-154 NNS denotes lines
T10570 179-188 VBN denotes developed
T10571 155-157 IN denotes of
T10572 158-168 JJ denotes transgenic
T10573 169-173 NNS denotes mice
T10574 174-178 VBD denotes were
T10575 189-192 IN denotes for
T10576 193-197 DT denotes this
T10577 198-203 NN denotes study
T10578 204-208 WDT denotes that
T10579 209-216 VBP denotes express
T10580 217-221 JJ denotes high
T10581 222-228 NNS denotes levels
T10582 229-231 IN denotes of
T10583 232-238 NN denotes APPswe
T10584 239-242 NN denotes ind
T10585 238-239 HYPH denotes /
T10586 243-248 IN denotes under
T10587 249-252 DT denotes the
T10588 253-260 NN denotes control
T10589 261-263 IN denotes of
T10590 264-265 DT denotes a
T10591 290-298 NN denotes promoter
T10592 266-278 NN denotes tetracycline
T10593 279-289 JJ denotes responsive
T10594 278-279 HYPH denotes -
T10595 298-299 . denotes .
T10596 299-497 sentence denotes We demonstrate that treatment with dox suppresses steady-state levels of both APPswe/ind and its C-terminal fragments, indicating that the mutant proteins have a relatively short half-life in vivo.
T10597 300-302 PRP denotes We
T10598 303-314 VBP denotes demonstrate
T10599 315-319 IN denotes that
T10600 339-349 VBZ denotes suppresses
T10601 320-329 NN denotes treatment
T10602 330-334 IN denotes with
T10603 335-338 NN denotes dox
T10604 350-356 JJ denotes steady
T10605 357-362 NN denotes state
T10606 356-357 HYPH denotes -
T10607 363-369 NNS denotes levels
T10608 370-372 IN denotes of
T10609 373-377 CC denotes both
T10610 385-388 NN denotes ind
T10611 378-384 NN denotes APPswe
T10612 384-385 HYPH denotes /
T10613 389-392 CC denotes and
T10614 393-396 PRP$ denotes its
T10615 408-417 NNS denotes fragments
T10616 397-398 NN denotes C
T10617 398-399 HYPH denotes -
T10618 399-407 JJ denotes terminal
T10619 417-419 , denotes ,
T10620 419-429 VBG denotes indicating
T10621 430-434 IN denotes that
T10622 455-459 VBP denotes have
T10623 435-438 DT denotes the
T10624 446-454 NN denotes proteins
T10625 439-445 NN denotes mutant
T10626 460-461 DT denotes a
T10627 484-488 NN denotes life
T10628 462-472 RB denotes relatively
T10629 473-478 JJ denotes short
T10630 479-483 NN denotes half
T10631 483-484 HYPH denotes -
T10632 489-491 FW denotes in
T10633 492-496 FW denotes vivo
T10634 496-497 . denotes .
T10635 497-677 sentence denotes Transgenic expression of APPswe/ind and consequent overproduction of Aβ42 cause early-onset amyloid deposition in untreated mice, in which deposits appear as early as 2 mo of age.
T10636 498-508 JJ denotes Transgenic
T10637 509-519 NN denotes expression
T10638 572-577 VBP denotes cause
T10639 520-522 IN denotes of
T10640 523-529 NN denotes APPswe
T10641 530-533 NN denotes ind
T10642 529-530 HYPH denotes /
T10643 534-537 CC denotes and
T10644 538-548 JJ denotes consequent
T10645 549-563 NN denotes overproduction
T10646 564-566 IN denotes of
T10647 567-571 NN denotes Aβ42
T10648 578-583 JJ denotes early
T10649 584-589 NN denotes onset
T10650 583-584 HYPH denotes -
T10651 598-608 NN denotes deposition
T10652 590-597 NN denotes amyloid
T10653 609-611 IN denotes in
T10654 612-621 JJ denotes untreated
T10655 622-626 NNS denotes mice
T10656 626-628 , denotes ,
T10657 628-630 IN denotes in
T10658 646-652 VBP denotes appear
T10659 631-636 WDT denotes which
T10660 637-645 NNS denotes deposits
T10661 653-655 RB denotes as
T10662 656-661 RB denotes early
T10663 662-664 IN denotes as
T10664 665-666 CD denotes 2
T10665 667-669 NN denotes mo
T10666 670-672 IN denotes of
T10667 673-676 NN denotes age
T10668 676-677 . denotes .
T10669 677-826 sentence denotes Amyloid burden worsens significantly with age, and by 9 mo, the hippocampus and cortex of untreated mice are largely filled with aggregated peptide.
T10670 678-685 NN denotes Amyloid
T10671 686-692 NN denotes burden
T10672 693-700 VBZ denotes worsens
T10673 701-714 RB denotes significantly
T10674 715-719 IN denotes with
T10675 720-723 NN denotes age
T10676 723-725 , denotes ,
T10677 725-728 CC denotes and
T10678 729-731 IN denotes by
T10679 795-801 VBN denotes filled
T10680 732-733 CD denotes 9
T10681 734-736 NN denotes mo
T10682 736-738 , denotes ,
T10683 738-741 DT denotes the
T10684 742-753 NN denotes hippocampus
T10685 754-757 CC denotes and
T10686 758-764 NN denotes cortex
T10687 765-767 IN denotes of
T10688 768-777 JJ denotes untreated
T10689 778-782 NNS denotes mice
T10690 783-786 VBP denotes are
T10691 787-794 RB denotes largely
T10692 802-806 IN denotes with
T10693 807-817 VBN denotes aggregated
T10694 818-825 NN denotes peptide
T10695 825-826 . denotes .
T10696 826-939 sentence denotes We find that suppression of transgenic APP by more than 95% abruptly halts the progression of amyloid pathology.
T10697 827-829 PRP denotes We
T10698 830-834 VBP denotes find
T10699 835-839 IN denotes that
T10700 896-901 VBZ denotes halts
T10701 840-851 NN denotes suppression
T10702 852-854 IN denotes of
T10703 855-865 JJ denotes transgenic
T10704 866-869 NN denotes APP
T10705 870-872 IN denotes by
T10706 873-877 JJR denotes more
T10707 883-885 CD denotes 95
T10708 878-882 IN denotes than
T10709 885-886 NN denotes %
T10710 887-895 RB denotes abruptly
T10711 902-905 DT denotes the
T10712 906-917 NN denotes progression
T10713 918-920 IN denotes of
T10714 921-928 NN denotes amyloid
T10715 929-938 NN denotes pathology
T10716 938-939 . denotes .
T10717 939-1132 sentence denotes Importantly, this outcome occurs in animals already harboring considerable amyloid pathology, a situation similar to what might be expected in patients to be treated with secretase inhibitors.
T10718 940-951 RB denotes Importantly
T10719 966-972 VBZ denotes occurs
T10720 951-953 , denotes ,
T10721 953-957 DT denotes this
T10722 958-965 NN denotes outcome
T10723 973-975 IN denotes in
T10724 976-983 NNS denotes animals
T10725 984-991 RB denotes already
T10726 992-1001 VBG denotes harboring
T10727 1002-1014 JJ denotes considerable
T10728 1023-1032 NN denotes pathology
T10729 1015-1022 NN denotes amyloid
T10730 1032-1034 , denotes ,
T10731 1034-1035 DT denotes a
T10732 1036-1045 NN denotes situation
T10733 1046-1053 JJ denotes similar
T10734 1054-1056 IN denotes to
T10735 1057-1061 WP denotes what
T10736 1071-1079 VBN denotes expected
T10737 1062-1067 MD denotes might
T10738 1068-1070 VB denotes be
T10739 1080-1082 IN denotes in
T10740 1083-1091 NNS denotes patients
T10741 1092-1094 TO denotes to
T10742 1098-1105 VBN denotes treated
T10743 1095-1097 VB denotes be
T10744 1106-1110 IN denotes with
T10745 1111-1120 NN denotes secretase
T10746 1121-1131 NNS denotes inhibitors
T10747 1131-1132 . denotes .
T10748 1132-1305 sentence denotes Somewhat unexpectedly, we observe no appreciable clearance of deposited amyloid even following periods of transgene suppression equal to the time taken for plaques to form.
T10749 1133-1141 RB denotes Somewhat
T10750 1142-1154 RB denotes unexpectedly
T10751 1159-1166 VBP denotes observe
T10752 1154-1156 , denotes ,
T10753 1156-1158 PRP denotes we
T10754 1167-1169 DT denotes no
T10755 1182-1191 NN denotes clearance
T10756 1170-1181 JJ denotes appreciable
T10757 1192-1194 IN denotes of
T10758 1195-1204 VBN denotes deposited
T10759 1205-1212 NN denotes amyloid
T10760 1213-1217 RB denotes even
T10761 1218-1227 VBG denotes following
T10762 1228-1235 NNS denotes periods
T10763 1236-1238 IN denotes of
T10764 1239-1248 NN denotes transgene
T10765 1249-1260 NN denotes suppression
T10766 1261-1266 JJ denotes equal
T10767 1267-1269 IN denotes to
T10768 1270-1273 DT denotes the
T10769 1274-1278 NN denotes time
T10770 1279-1284 VBN denotes taken
T10771 1285-1288 IN denotes for
T10772 1300-1304 VB denotes form
T10773 1289-1296 NNS denotes plaques
T10774 1297-1299 TO denotes to
T10775 1304-1305 . denotes .
T10776 1305-1523 sentence denotes This latter finding indicates that compared to other disease-associated protein aggregates such as mutant huntingtin, which clear in less than 3 mo [32], the disaggregation of extracellular amyloid is relatively slow.
T10777 1306-1310 DT denotes This
T10778 1318-1325 NN denotes finding
T10779 1311-1317 JJ denotes latter
T10780 1326-1335 VBZ denotes indicates
T10781 1336-1340 IN denotes that
T10782 1504-1506 VBZ denotes is
T10783 1341-1349 VBN denotes compared
T10784 1350-1352 IN denotes to
T10785 1353-1358 JJ denotes other
T10786 1386-1396 NNS denotes aggregates
T10787 1359-1366 NN denotes disease
T10788 1367-1377 VBN denotes associated
T10789 1366-1367 HYPH denotes -
T10790 1378-1385 NN denotes protein
T10791 1397-1401 JJ denotes such
T10792 1402-1404 IN denotes as
T10793 1405-1411 NN denotes mutant
T10794 1412-1422 NN denotes huntingtin
T10795 1422-1424 , denotes ,
T10796 1424-1429 WDT denotes which
T10797 1430-1435 VBP denotes clear
T10798 1436-1438 IN denotes in
T10799 1439-1443 JJR denotes less
T10800 1449-1450 CD denotes 3
T10801 1444-1448 IN denotes than
T10802 1451-1453 NN denotes mo
T10803 1454-1455 -LRB- denotes [
T10804 1455-1457 CD denotes 32
T10805 1457-1458 -RRB- denotes ]
T10806 1458-1460 , denotes ,
T10807 1460-1463 DT denotes the
T10808 1464-1478 NN denotes disaggregation
T10809 1479-1481 IN denotes of
T10810 1482-1495 JJ denotes extracellular
T10811 1496-1503 NN denotes amyloid
T10812 1507-1517 RB denotes relatively
T10813 1518-1522 JJ denotes slow
T10814 1522-1523 . denotes .
R6986 T10541 T10542 nsubj We,present
R6987 T10543 T10544 det a,model
R6988 T10544 T10542 dobj model,present
R6989 T10545 T10544 amod new,model
R6990 T10546 T10544 compound mouse,model
R6991 T10547 T10544 prep for,model
R6992 T10548 T10547 pobj AD,for
R6993 T10549 T10550 dep that,designed
R6994 T10550 T10544 relcl designed,model
R6995 T10551 T10550 auxpass was,designed
R6996 T10552 T10553 aux to,test
R6997 T10553 T10550 advcl test,designed
R6998 T10554 T10555 det the,consequences
R6999 T10555 T10553 dobj consequences,test
R7000 T10556 T10555 prep of,consequences
R7001 T10557 T10556 pcomp inhibiting,of
R7002 T10558 T10559 compound Aβ,production
R7003 T10559 T10557 dobj production,inhibiting
R7004 T10560 T10557 prep after,inhibiting
R7005 T10561 T10562 det the,onset
R7006 T10562 T10560 pobj onset,after
R7007 T10563 T10562 prep of,onset
R7008 T10564 T10565 compound amyloid,pathology
R7009 T10565 T10563 pobj pathology,of
R7010 T10566 T10542 punct .,present
R7011 T10568 T10569 amod New,lines
R7012 T10569 T10570 nsubjpass lines,developed
R7013 T10571 T10569 prep of,lines
R7014 T10572 T10573 amod transgenic,mice
R7015 T10573 T10571 pobj mice,of
R7016 T10574 T10570 auxpass were,developed
R7017 T10575 T10570 prep for,developed
R7018 T10576 T10577 det this,study
R7019 T10577 T10575 pobj study,for
R7020 T10578 T10579 dep that,express
R7021 T10579 T10570 ccomp express,developed
R7022 T10580 T10581 amod high,levels
R7023 T10581 T10579 dobj levels,express
R7024 T10582 T10581 prep of,levels
R7025 T10583 T10584 compound APPswe,ind
R7026 T10584 T10582 pobj ind,of
R7027 T10585 T10584 punct /,ind
R7028 T10586 T10579 prep under,express
R7029 T10587 T10588 det the,control
R7030 T10588 T10586 pobj control,under
R7031 T10589 T10588 prep of,control
R7032 T10590 T10591 det a,promoter
R7033 T10591 T10589 pobj promoter,of
R7034 T10592 T10593 npadvmod tetracycline,responsive
R7035 T10593 T10591 amod responsive,promoter
R7036 T10594 T10593 punct -,responsive
R7037 T10595 T10570 punct .,developed
R7038 T10597 T10598 nsubj We,demonstrate
R7039 T10599 T10600 mark that,suppresses
R7040 T10600 T10598 ccomp suppresses,demonstrate
R7041 T10601 T10600 nsubj treatment,suppresses
R7042 T10602 T10601 prep with,treatment
R7043 T10603 T10602 pobj dox,with
R7044 T10604 T10605 amod steady,state
R7045 T10605 T10607 compound state,levels
R7046 T10606 T10605 punct -,state
R7047 T10607 T10600 dobj levels,suppresses
R7048 T10608 T10607 prep of,levels
R7049 T10609 T10610 preconj both,ind
R7050 T10610 T10608 pobj ind,of
R7051 T10611 T10610 compound APPswe,ind
R7052 T10612 T10610 punct /,ind
R7053 T10613 T10610 cc and,ind
R7054 T10614 T10615 poss its,fragments
R7055 T10615 T10610 conj fragments,ind
R7056 T10616 T10615 nmod C,fragments
R7057 T10617 T10615 punct -,fragments
R7058 T10618 T10615 amod terminal,fragments
R7059 T10619 T10600 punct ", ",suppresses
R7060 T10620 T10600 advcl indicating,suppresses
R7061 T10621 T10622 mark that,have
R7062 T10622 T10620 ccomp have,indicating
R7063 T10623 T10624 det the,proteins
R7064 T10624 T10622 nsubj proteins,have
R7065 T10625 T10624 compound mutant,proteins
R7066 T10626 T10627 det a,life
R7067 T10627 T10622 dobj life,have
R7068 T10628 T10629 advmod relatively,short
R7069 T10629 T10627 amod short,life
R7070 T10630 T10627 compound half,life
R7071 T10631 T10627 punct -,life
R7072 T10632 T10633 advmod in,vivo
R7073 T10633 T10622 advmod vivo,have
R7074 T10634 T10598 punct .,demonstrate
R7075 T10636 T10637 amod Transgenic,expression
R7076 T10637 T10638 nsubj expression,cause
R7077 T10639 T10637 prep of,expression
R7078 T10640 T10641 compound APPswe,ind
R7079 T10641 T10639 pobj ind,of
R7080 T10642 T10641 punct /,ind
R7081 T10643 T10637 cc and,expression
R7082 T10644 T10645 amod consequent,overproduction
R7083 T10645 T10637 conj overproduction,expression
R7084 T10646 T10645 prep of,overproduction
R7085 T10647 T10646 pobj Aβ42,of
R7086 T10648 T10649 amod early,onset
R7087 T10649 T10651 compound onset,deposition
R7088 T10650 T10649 punct -,onset
R7089 T10651 T10638 dobj deposition,cause
R7090 T10652 T10651 compound amyloid,deposition
R7091 T10653 T10638 prep in,cause
R7092 T10654 T10655 amod untreated,mice
R7093 T10655 T10653 pobj mice,in
R7094 T10656 T10655 punct ", ",mice
R7095 T10657 T10658 prep in,appear
R7096 T10658 T10655 relcl appear,mice
R7097 T10659 T10657 pobj which,in
R7098 T10660 T10658 nsubj deposits,appear
R7099 T10661 T10662 advmod as,early
R7100 T10662 T10658 advmod early,appear
R7101 T10663 T10662 prep as,early
R7102 T10664 T10665 nummod 2,mo
R7103 T10665 T10663 pobj mo,as
R7104 T10666 T10665 prep of,mo
R7105 T10667 T10666 pobj age,of
R7106 T10668 T10638 punct .,cause
R7107 T10670 T10671 compound Amyloid,burden
R7108 T10671 T10672 nsubj burden,worsens
R7109 T10673 T10672 advmod significantly,worsens
R7110 T10674 T10672 prep with,worsens
R7111 T10675 T10674 pobj age,with
R7112 T10676 T10672 punct ", ",worsens
R7113 T10677 T10672 cc and,worsens
R7114 T10678 T10679 prep by,filled
R7115 T10679 T10672 conj filled,worsens
R7116 T10680 T10681 nummod 9,mo
R7117 T10681 T10678 pobj mo,by
R7118 T10682 T10679 punct ", ",filled
R7119 T10683 T10684 det the,hippocampus
R7120 T10684 T10679 nsubjpass hippocampus,filled
R7121 T10685 T10684 cc and,hippocampus
R7122 T10686 T10684 conj cortex,hippocampus
R7123 T10687 T10684 prep of,hippocampus
R7124 T10688 T10689 amod untreated,mice
R7125 T10689 T10687 pobj mice,of
R7126 T10690 T10679 auxpass are,filled
R7127 T10691 T10679 advmod largely,filled
R7128 T10692 T10679 prep with,filled
R7129 T10693 T10694 amod aggregated,peptide
R7130 T10694 T10692 pobj peptide,with
R7131 T10695 T10679 punct .,filled
R7132 T10697 T10698 nsubj We,find
R7133 T10699 T10700 mark that,halts
R7134 T10700 T10698 ccomp halts,find
R7135 T10701 T10700 nsubj suppression,halts
R7136 T10702 T10701 prep of,suppression
R7137 T10703 T10704 amod transgenic,APP
R7138 T10704 T10702 pobj APP,of
R7139 T10705 T10701 prep by,suppression
R7140 T10706 T10707 amod more,95
R7141 T10707 T10709 nummod 95,%
R7142 T10708 T10707 quantmod than,95
R7143 T10709 T10705 pobj %,by
R7144 T10710 T10700 advmod abruptly,halts
R7145 T10711 T10712 det the,progression
R7146 T10712 T10700 dobj progression,halts
R7147 T10713 T10712 prep of,progression
R7148 T10714 T10715 compound amyloid,pathology
R7149 T10715 T10713 pobj pathology,of
R7150 T10716 T10698 punct .,find
R7151 T10718 T10719 advmod Importantly,occurs
R7152 T10720 T10719 punct ", ",occurs
R7153 T10721 T10722 det this,outcome
R7154 T10722 T10719 nsubj outcome,occurs
R7155 T10723 T10719 prep in,occurs
R7156 T10724 T10723 pobj animals,in
R7157 T10725 T10726 advmod already,harboring
R7158 T10726 T10724 acl harboring,animals
R7159 T10727 T10728 amod considerable,pathology
R7160 T10728 T10726 dobj pathology,harboring
R7161 T10729 T10728 compound amyloid,pathology
R7162 T10730 T10719 punct ", ",occurs
R7163 T10731 T10732 det a,situation
R7164 T10732 T10719 npadvmod situation,occurs
R7165 T10733 T10732 amod similar,situation
R7166 T10734 T10733 prep to,similar
R7167 T10735 T10736 dep what,expected
R7168 T10736 T10734 pcomp expected,to
R7169 T10737 T10736 aux might,expected
R7170 T10738 T10736 auxpass be,expected
R7171 T10739 T10736 prep in,expected
R7172 T10740 T10739 pobj patients,in
R7173 T10741 T10742 aux to,treated
R7174 T10742 T10740 advcl treated,patients
R7175 T10743 T10742 auxpass be,treated
R7176 T10744 T10742 prep with,treated
R7177 T10745 T10746 compound secretase,inhibitors
R7178 T10746 T10744 pobj inhibitors,with
R7179 T10747 T10719 punct .,occurs
R7180 T10749 T10750 advmod Somewhat,unexpectedly
R7181 T10750 T10751 advmod unexpectedly,observe
R7182 T10752 T10751 punct ", ",observe
R7183 T10753 T10751 nsubj we,observe
R7184 T10754 T10755 det no,clearance
R7185 T10755 T10751 dobj clearance,observe
R7186 T10756 T10755 amod appreciable,clearance
R7187 T10757 T10755 prep of,clearance
R7188 T10758 T10759 amod deposited,amyloid
R7189 T10759 T10757 pobj amyloid,of
R7190 T10760 T10761 advmod even,following
R7191 T10761 T10751 prep following,observe
R7192 T10762 T10761 pobj periods,following
R7193 T10763 T10762 prep of,periods
R7194 T10764 T10765 compound transgene,suppression
R7195 T10765 T10763 pobj suppression,of
R7196 T10766 T10762 amod equal,periods
R7197 T10767 T10766 prep to,equal
R7198 T10768 T10769 det the,time
R7199 T10769 T10767 pobj time,to
R7200 T10770 T10769 advcl taken,time
R7201 T10771 T10772 mark for,form
R7202 T10772 T10770 advcl form,taken
R7203 T10773 T10772 nsubj plaques,form
R7204 T10774 T10772 aux to,form
R7205 T10775 T10751 punct .,observe
R7206 T10777 T10778 det This,finding
R7207 T10778 T10780 nsubj finding,indicates
R7208 T10779 T10778 amod latter,finding
R7209 T10781 T10782 mark that,is
R7210 T10782 T10780 ccomp is,indicates
R7211 T10783 T10782 prep compared,is
R7212 T10784 T10783 prep to,compared
R7213 T10785 T10786 amod other,aggregates
R7214 T10786 T10784 pobj aggregates,to
R7215 T10787 T10788 npadvmod disease,associated
R7216 T10788 T10786 amod associated,aggregates
R7217 T10789 T10788 punct -,associated
R7218 T10790 T10786 compound protein,aggregates
R7219 T10791 T10792 amod such,as
R7220 T10792 T10786 prep as,aggregates
R7221 T10793 T10794 compound mutant,huntingtin
R7222 T10794 T10792 pobj huntingtin,as
R7223 T10795 T10794 punct ", ",huntingtin
R7224 T10796 T10797 dep which,clear
R7225 T10797 T10794 relcl clear,huntingtin
R7226 T10798 T10797 prep in,clear
R7227 T10799 T10800 amod less,3
R7228 T10800 T10802 nummod 3,mo
R7229 T10801 T10800 quantmod than,3
R7230 T10802 T10798 pobj mo,in
R7231 T10803 T10804 punct [,32
R7232 T10804 T10797 parataxis 32,clear
R7233 T10805 T10804 punct ],32
R7234 T10806 T10782 punct ", ",is
R7235 T10807 T10808 det the,disaggregation
R7236 T10808 T10782 nsubj disaggregation,is
R7237 T10809 T10808 prep of,disaggregation
R7238 T10810 T10811 amod extracellular,amyloid
R7239 T10811 T10809 pobj amyloid,of
R7240 T10812 T10813 advmod relatively,slow
R7241 T10813 T10782 acomp slow,is
R7242 T10814 T10780 punct .,indicates

2_test

Id Subject Object Predicate Lexical cue
16279840-10778856-86242777 1455-1457 10778856 denotes 32
T17182 1455-1457 10778856 denotes 32

craft-ca-core-ex-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue
T10200 17-22 NCBITaxon:10088 denotes mouse
T10201 93-95 CHEBI_PR_EXT:amyloid_beta denotes Aβ
T10202 93-106 GO:0034205 denotes Aβ production
T10203 126-133 CHEBI:60425 denotes amyloid
T10204 158-168 SO_EXT:transgenic_entity denotes transgenic
T10205 169-173 NCBITaxon:10088 denotes mice
T10206 209-216 GO:0010467 denotes express
T10207 253-260 GO:0065007 denotes control
T10208 266-278 CHEBI:27902 denotes tetracycline
T10209 290-298 SO_EXT:0000167 denotes promoter
T10210 335-338 CHEBI:50845 denotes dox
T10211 397-407 CHEBI_SO_EXT:C_terminus_or_C_terminal_region denotes C-terminal
T10212 439-445 SO_EXT:sequence_altered_entity_or_alteration_process denotes mutant
T10213 446-454 CHEBI_PR_EXT:protein denotes proteins
T10214 498-508 SO_EXT:transgenic_entity denotes Transgenic
T10215 509-519 GO:0010467 denotes expression
T10216 567-571 CHEBI_PR_EXT:amyloid_beta_42 denotes Aβ42
T10217 590-597 CHEBI:60425 denotes amyloid
T10218 622-626 NCBITaxon:10088 denotes mice
T10219 678-685 CHEBI:60425 denotes Amyloid
T10220 742-753 UBERON_EXT:hippocampus_proper_or_hippocampal_formation denotes hippocampus
T10221 758-764 UBERON:0001851 denotes cortex
T10222 778-782 NCBITaxon:10088 denotes mice
T10223 818-825 CHEBI_SO_EXT:peptide_or_peptide_region denotes peptide
T10224 855-865 SO_EXT:transgenic_entity denotes transgenic
T10225 866-869 PR_EXT:000004168 denotes APP
T10226 921-928 CHEBI:60425 denotes amyloid
T10227 976-983 NCBITaxon:33208 denotes animals
T10228 1015-1022 CHEBI:60425 denotes amyloid
T10229 1121-1131 CHEBI_EXT:35222 denotes inhibitors
T10230 1205-1212 CHEBI:60425 denotes amyloid
T10231 1239-1248 SO_EXT:0000902 denotes transgene
T10232 1378-1385 CHEBI_PR_EXT:protein denotes protein
T10233 1405-1411 SO_EXT:sequence_altered_entity_or_alteration_process denotes mutant
T10234 1412-1422 PR_EXT:000008840 denotes huntingtin
T10235 1482-1495 GO:0005576 denotes extracellular
T10236 1487-1495 CL_GO_EXT:cell denotes cellular
T10237 1496-1503 CHEBI:60425 denotes amyloid

craft-ca-core-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue
T9940 17-22 NCBITaxon:10088 denotes mouse
T9941 93-106 GO:0034205 denotes Aβ production
T9942 126-133 CHEBI:60425 denotes amyloid
T9943 169-173 NCBITaxon:10088 denotes mice
T9944 209-216 GO:0010467 denotes express
T9945 253-260 GO:0065007 denotes control
T9946 266-278 CHEBI:27902 denotes tetracycline
T9947 290-298 SO:0000167 denotes promoter
T9948 335-338 CHEBI:50845 denotes dox
T9949 509-519 GO:0010467 denotes expression
T9950 590-597 CHEBI:60425 denotes amyloid
T9951 622-626 NCBITaxon:10088 denotes mice
T9952 678-685 CHEBI:60425 denotes Amyloid
T9953 758-764 UBERON:0001851 denotes cortex
T9954 778-782 NCBITaxon:10088 denotes mice
T9955 866-869 PR:000004168 denotes APP
T9956 921-928 CHEBI:60425 denotes amyloid
T9957 976-983 NCBITaxon:33208 denotes animals
T9958 1015-1022 CHEBI:60425 denotes amyloid
T9959 1121-1131 CHEBI:35222 denotes inhibitors
T9960 1205-1212 CHEBI:60425 denotes amyloid
T9961 1239-1248 SO:0000902 denotes transgene
T9962 1412-1422 PR:000008840 denotes huntingtin
T9963 1482-1495 GO:0005576 denotes extracellular
T9964 1496-1503 CHEBI:60425 denotes amyloid